Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?
08:27am, Friday, 10'th Sep 2021
MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase
Why MacroGenics Soared Nearly 9% Higher Today
06:57pm, Thursday, 09'th Sep 2021
Investors are signaling hope in the company's top drug, despite a disappointing final analysis.
MacroGenics study shows breast-cancer drug survival rates fell short
04:54pm, Tuesday, 07'th Sep 2021
MacroGenics Inc. MGNX, -3.20% shares were halted late Tuesday after the biotech drug developer said its breast-cancer treatment didn't perform as well as standard treatment in a late-stage clinical st
ROCKVILLE, MD, Sept. 07, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut
MacroGenics to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 02'nd Sep 2021
ROCKVILLE, MD, Sept. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut
Why MacroGenics Stock Is Tumbling Today
11:47am, Friday, 30'th Jul 2021
The company provided its Q2 update.
MacroGenics' (MGNX) CEO Scott Koenig on Q2 2021 Results - Earnings Call Transcript
02:37am, Friday, 30'th Jul 2021
MacroGenics' (MGNX) CEO Scott Koenig on Q2 2021 Results - Earnings Call Transcript
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
07:46pm, Thursday, 29'th Jul 2021
MacroGenics (MGNX) delivered earnings and revenue surprises of -135.71% and -13.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
04:05pm, Thursday, 22'nd Jul 2021
ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
05:35pm, Wednesday, 16'th Jun 2021
NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advis
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
07:30am, Wednesday, 16'th Jun 2021
ROCKVILLE, MD, SHANGHAI and SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
04:31pm, Saturday, 12'th Jun 2021
New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
05:35pm, Tuesday, 08'th Jun 2021
NEW YORK, June 8, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised
Why MacroGenics Stock Is Tumbling Today
11:52am, Thursday, 20'th May 2021
The company announced preliminary phase 1 results for its tumor-fighting drug MGC018.
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
05:05pm, Wednesday, 19'th May 2021
ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic
